Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

James D. Neaton, Abdel Babiker, Mark Bohnhorst, Janet Darbyshire, Eileen Denning, Arnie Frishman, Jesper Grarup, Gregg Larson, Jens Lundgren

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Background A number of reports have highlighted problems of conducting publicly funded trials in Europe as a consequence of the European Union (EU) Clinical Trials Directive. The impact of the EU Directive on multi-national trials, which include sites in Europe that are funded by the US National Institutes of Health (NIH) have not been described. Methods Four problems in the conduct of two international HIV treatment trials funded by NIH in the EU are described: (1) conflicting regulations on the continuing review of protocols by Institutional Review Boards/Research Ethics Committees; (2) US regulations requiring Federalwide Assurances for sites which are only partially funded by NIH; (3) EU guidance on the designation of studies as a trial of an investigational medicinal product; and (4) EU guidance on trial sponsorship and the requirements for insurance and indemnification. Following the description of the problems, recommendations for improving global collaborations are made to the US Office of Human Research Protections, to NIH, and to the EU and its Member States. Results A lack of harmonization of regulations at multiple levels caused enrollment in one study to be interrupted for several months and delayed for one year the initiation of another study aimed at obtaining definitive evidence to guide the timing of the initiation of antiretroviral therapy for individuals infected with HIV. The delays and the purchase of insurance resulted in substantial increases in trial costs and caused substantial disruption at clinical sites among staff and study participants. Limitations The problems cited and recommendations made pertain to trials funded by NIH and conducted by sites in the EU. There are many other challenges in the conduct of international research, public and private, that global harmonization would alleviate. Conclusions Disharmony, at multiple levels, in international regulations and guidelines is stifling publicly funded global research. International scientific organizations and government groups should make the documentation and solution of these problems a priority.

Original languageEnglish (US)
Pages (from-to)705-718
Number of pages14
JournalClinical Trials
Issue number6
StatePublished - Dec 2010

Bibliographical note

Copyright 2011 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health'. Together they form a unique fingerprint.

Cite this